These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 21254698

  • 1. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients].
    Shiota J, Izumi N, Kasahara H, Tagawa H, Chiba T, Nihei H.
    Nihon Jinzo Gakkai Shi; 2010; 52(8):1022-8. PubMed ID: 21254698
    [Abstract] [Full Text] [Related]

  • 2. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [Abstract] [Full Text] [Related]

  • 3. Serum Tartrate-resistant Acid Phosphatase-5b Levels are Associated with the Severity and Extent of Coronary Atherosclerosis in Patients with Coronary Artery Disease.
    Morisawa T, Nakagomi A, Kohashi K, Kusama Y, Shimizu W.
    J Atheroscler Thromb; 2017 Oct 01; 24(10):1058-1068. PubMed ID: 28428481
    [Abstract] [Full Text] [Related]

  • 4. [Measurement and clinical significance of serum DKK-1 and sRANKL levels in multiple myeloma].
    Bao L, Huang XJ.
    Zhonghua Nei Ke Za Zhi; 2011 Mar 01; 50(3):243-7. PubMed ID: 21600091
    [Abstract] [Full Text] [Related]

  • 5. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X, Goldman JM, Rahemtulla A.
    Int J Cancer; 2003 Sep 01; 106(3):455-7. PubMed ID: 12845688
    [Abstract] [Full Text] [Related]

  • 6. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients.
    Mikami S, Hamano T, Fujii N, Nagasawa Y, Isaka Y, Moriyama T, Matsuhisa M, Ito T, Imai E, Hori M.
    Hypertens Res; 2008 Jun 01; 31(6):1163-70. PubMed ID: 18716364
    [Abstract] [Full Text] [Related]

  • 7. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Tziamalis MP, Tsigris C, Kostaki MA, Perrea DN.
    J Endocrinol Invest; 2007 Oct 01; 30(9):762-6. PubMed ID: 17993768
    [Abstract] [Full Text] [Related]

  • 8. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I, Balon BP, Rus I, Marc J.
    Nephrol Dial Transplant; 2005 Mar 01; 20(3):566-70. PubMed ID: 15665031
    [Abstract] [Full Text] [Related]

  • 9. Biochemical markers of vascular calcification in elderly hemodialysis patients.
    Osorio A, Ortega E, Torres JM, Sanchez P, Ruiz-Requena E.
    Mol Cell Biochem; 2013 Feb 01; 374(1-2):21-7. PubMed ID: 23124853
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
    Liu J, Xu K, Wen G, Guo H, Li S, Wu X, Dai R, Sheng Z, Liao E.
    Bone; 2008 May 01; 42(5):950-9. PubMed ID: 18337202
    [Abstract] [Full Text] [Related]

  • 11. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E.
    Acta Oncol; 2007 May 01; 46(2):221-9. PubMed ID: 17453373
    [Abstract] [Full Text] [Related]

  • 12. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
    Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI.
    Br J Haematol; 2006 Dec 01; 135(5):688-92. PubMed ID: 17107351
    [Abstract] [Full Text] [Related]

  • 13. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
    Rissanen JP, Suominen MI, Peng Z, Halleen JM.
    Calcif Tissue Int; 2008 Feb 01; 82(2):108-15. PubMed ID: 18084692
    [Abstract] [Full Text] [Related]

  • 14. Mineral-bone metabolism markers in young hemodialysis patients.
    Osorio A, Ortega E, Torres JM, Sanchez P, Ruiz-Requena E.
    Clin Biochem; 2011 Dec 01; 44(17-18):1425-8. PubMed ID: 21933667
    [Abstract] [Full Text] [Related]

  • 15. Predictive Value of Osteoprotegerin for Detecting Coronary Artery Calcification in Type 2 Diabetes Mellitus Patients in Correlation with Extent of Calcification Detected by Multidetector Computed Tomography.
    Ahmed S, Sobh R.
    Endocr Metab Immune Disord Drug Targets; 2019 Dec 01; 19(6):845-851. PubMed ID: 30747085
    [Abstract] [Full Text] [Related]

  • 16. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
    Evans CE, Mylchreest S, Andrew JG.
    BMC Musculoskelet Disord; 2006 Mar 06; 7():21. PubMed ID: 16519799
    [Abstract] [Full Text] [Related]

  • 17. High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice.
    Bargman R, Posham R, Boskey A, Carter E, DiCarlo E, Verdelis K, Raggio C, Pleshko N.
    Pediatr Res; 2012 Nov 06; 72(5):495-501. PubMed ID: 22926546
    [Abstract] [Full Text] [Related]

  • 18. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A.
    Br J Haematol; 2004 Sep 06; 126(5):686-9. PubMed ID: 15327520
    [Abstract] [Full Text] [Related]

  • 19. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
    Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ.
    Bone; 2009 Oct 06; 45(4):669-76. PubMed ID: 19539794
    [Abstract] [Full Text] [Related]

  • 20. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum].
    Uchida K, Nakanishi M, Yoh K.
    Rinsho Byori; 2001 Jan 06; 49(1):51-5. PubMed ID: 11215484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.